1-3 of 3
James Pring
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers

Niroshana Anandasabapathy, MD, PhD, Arlene Hurley, ANP, CCRC, Marina Caskey, Christine Trumpfheller, Popi Sarma, James Pring, Maggie Pack, Renee Riggs, Jennifer Green, Michael Yellin, MD, Thomas A. Davis, MD, Tibor Keler, PhD, Sarah Schlesinger, MD
Journal: Blood
Blood (2012) 120 (21): 4124.
https://doi.org/10.1182/blood.V120.21.4124.4124
Published: 2012
Journal Articles

Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation

Brief Report
Jeffrey M. Venstrom, Ted A. Gooley, Stephen Spellman, James Pring, Mari Malkki, Bo Dupont, Effie Petersdorf, Katharine C. Hsu
Journal: Blood
Blood (2010) 115 (15): 3162–3165.
https://doi.org/10.1182/blood-2009-08-236943
Published: 2010
Includes: Supplemental data
Journal Articles

Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell–depleted allogeneic hematopoietic cell transplantation

Junli Yu, Jeffrey M. Venstrom, Xiao-Rong Liu, James Pring, Reenat S. Hasan, Richard J. O'Reilly, Katharine C. Hsu
Journal: Blood
Blood (2009) 113 (16): 3875–3884.
https://doi.org/10.1182/blood-2008-09-177055
Published: 2009
Includes: Supplemental data